You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Ulixertinib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Ulixertinib?

Ulixertinib is an investigational drug.

There have been 11 clinical trials for Ulixertinib. The most recent clinical trial was a Phase 1 trial, which was initiated on March 26th 2018.

The most common disease conditions in clinical trials are Glioma, Neoplasms, and Lymphoma. The leading clinical trial sponsors are BioMed Valley Discoveries, Inc, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are eighteen US patents protecting this investigational drug and two hundred and nine international patents.

Recent Clinical Trials for Ulixertinib
TitleSponsorPhase
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyBioMed Valley Discoveries, IncPhase 1
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyEli Lilly and CompanyPhase 1
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyM.D. Anderson Cancer CenterPhase 1

See all Ulixertinib clinical trials

Clinical Trial Summary for Ulixertinib

Top disease conditions for Ulixertinib
trials011223344GliomaNeoplasmsLymphomaSarcoma[disabled in preview]
Top clinical trial sponsors for Ulixertinib
trials012345678BioMed Valley Discoveries, IncNational Cancer Institute (NCI)M.D. Anderson Cancer Center[disabled in preview]

See all Ulixertinib clinical trials

US Patents for Ulixertinib

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Ulixertinib ⤷  Subscribe Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH) ⤷  Subscribe
Ulixertinib ⤷  Subscribe Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Subscribe
Ulixertinib ⤷  Subscribe Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2 Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA) ⤷  Subscribe
Ulixertinib ⤷  Subscribe Point mutations in TRK inhibitor-resistant cancer and methods relating to the same Loxo Oncology, Inc. (Stamford, CT) Array Biopharma, Inc. (Boulder, CO) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 4 of 4 entries

International Patents for Ulixertinib

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Ulixertinib Argentina AR097326 1989-12-31 ⤷  Subscribe
Ulixertinib Australia AU2014307593 1989-12-31 ⤷  Subscribe
Ulixertinib Brazil BR112016001783 1989-12-31 ⤷  Subscribe
Ulixertinib Canada CA2921300 1989-12-31 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 4 of 4 entries

Ulixertinib: A Promising ERK Inhibitor in Cancer Treatment

Introduction to Ulixertinib

Ulixertinib, also known as BVD-523, is a novel oral ERK1/2 inhibitor developed by BioMed Valley Discoveries. It has shown significant promise in treating various types of cancers, particularly those with MAPK pathway mutations. Here, we will delve into the current development status, clinical trials, and market projections for this drug candidate.

Mechanism of Action and Selectivity

Ulixertinib is distinguished by its highly selective inhibition of ERK1, ERK2, and ERK8, with minimal off-target effects. This selectivity is crucial as it reduces the risk of adverse events and enhances the drug's efficacy. Unlike other ERK inhibitors, ulixertinib's targeted approach helps in maintaining the delicate balance of the MAPK pathway, avoiding the reactivation of ERK kinases that can occur with less selective inhibitors[1][2].

Clinical Development Program

Adult Clinical Studies

Ulixertinib has been extensively studied in adult patients across various cancer types, including glioma, histiocytosis, melanoma, pancreatic, and colorectal cancers. The clinical development program includes:

  • Phase 1b and Phase 2 Trials: Over 400 patients have been treated, with a recommended Phase 2 dose (RP2D) established at 600 mg twice daily (BID) for adults. The drug has shown clinical activity and a favorable tolerability profile[1].
  • Combination Therapies: Ulixertinib is being explored in combination with other therapies such as palbociclib and hydroxychloroquine (HCQ). The combination approach aims to address high unmet patient needs, particularly in tumors with documented frequency of MAPK pathway mutations and limited treatment options[1].

Pediatric Clinical Studies

  • Pediatric MATCH Trial: This Phase II trial is investigating the efficacy of ulixertinib in pediatric patients with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that harbor activating genetic alterations in the MAPK pathway. The trial aims to determine the objective response rate, progression-free survival, and tolerability of ulixertinib in children and adolescents[3].
  • Established Pediatric Dose: The recommended Phase 2 dose for pediatrics has been established at 260 mg/m²/dose PO BID, with plans to expand this dose in a pediatric low-grade glioma study in 2024[1].

Specific Clinical Trials and Outcomes

Phase Ib Study with Gemcitabine and Nab-Paclitaxel

In a Phase Ib trial, ulixertinib was combined with gemcitabine and nab-paclitaxel for untreated metastatic pancreatic adenocarcinoma. Although the study was prematurely terminated due to poor tolerability at the initial dose of 600 mg BID, which was later adjusted to 450 mg BID, it showed promising results. One patient achieved a partial response, and two patients achieved stable disease. The median progression-free survival (PFS) and overall survival (OS) were 5.46 and 12.23 months, respectively[2].

Compassionate Use Program

xCures has launched a Compassionate Use program for ulixertinib, providing access to this drug for advanced cancer patients with MAPK pathway-altered solid tumors who have exhausted other treatment options. This program underscores the potential of ulixertinib in addressing unmet medical needs in a compassionate setting[5].

Market Projections and Likelihood of Approval

Indications and Target Markets

Ulixertinib is being developed for a wide range of cancer types, including metastatic uveal melanoma, metastatic melanoma, non-small cell lung cancer, acute myelogenous leukemia, colorectal cancer, and others. Its broad potential in both solid and liquid tumors positions it as a versatile treatment option in the oncology market[4].

Likelihood of Approval

GlobalData's analysis suggests that while there is limited historical data for Phase II drugs in hematological tumors, ulixertinib's unique mechanism and clinical data support a positive outlook. The drug's performance in clinical trials, particularly its selectivity and tolerability profile, are key factors that could influence its likelihood of approval[4].

Partnering Opportunities

BioMed Valley Discoveries is actively seeking early development partners to explore ulixertinib's potential in combination with other MAPK pathway inhibitors and auxiliary pathway inhibitors. This partner-centric strategy aims to leverage the drug's differentiated profile to address high unmet patient needs in various cancer indications[1].

Challenges and Future Directions

Tolerability and Dosing

While ulixertinib has shown a favorable tolerability profile, some studies have required dose adjustments due to adverse events. The ability to dose ulixertinib intermittently without sacrificing efficacy, as observed in compassionate use settings, is a positive indicator but requires further investigation[1][2].

Combination Therapies

The future of ulixertinib lies in its potential to be combined with other therapeutic agents. Ongoing and planned studies focusing on combinations with JAK inhibitors, RAS inhibitors, and RAF inhibitors are critical for expanding its therapeutic scope and improving patient outcomes[1].

Key Takeaways

  • Highly Selective ERK Inhibition: Ulixertinib's selective inhibition of ERK1, ERK2, and ERK8 distinguishes it from other ERK inhibitors.
  • Broad Clinical Development: The drug is being studied in various adult and pediatric cancer types, including glioma, melanoma, and pancreatic cancer.
  • Promising Clinical Activity: Ulixertinib has shown clinical activity and a favorable tolerability profile in several clinical trials.
  • Market Potential: With its broad range of indications and potential for combination therapies, ulixertinib holds significant market potential in the oncology sector.
  • Partnering Opportunities: BioMed Valley Discoveries is seeking partners to further develop ulixertinib in combination with other therapeutic agents.

FAQs

Q: What is the mechanism of action of ulixertinib?

A: Ulixertinib is a highly selective inhibitor of ERK1, ERK2, and ERK8, targeting the MAPK pathway to inhibit cancer cell growth.

Q: Which cancer types is ulixertinib being studied for?

A: Ulixertinib is being studied for various cancer types, including glioma, melanoma, pancreatic cancer, colorectal cancer, and hematological tumors.

Q: What is the current stage of clinical development for ulixertinib?

A: Ulixertinib is currently in Phase II clinical trials for several indications, with ongoing and planned studies in both adult and pediatric populations.

Q: What are the common adverse events associated with ulixertinib?

A: Common treatment-related adverse events include anemia, thrombocytopenia, rash, and diarrhea, although the drug generally has a favorable tolerability profile.

Q: Is ulixertinib available for compassionate use?

A: Yes, ulixertinib is available through a Compassionate Use program for advanced cancer patients with MAPK pathway-altered solid tumors who have exhausted other treatment options.

Sources

  1. Biomed Valley Discoveries. Ulixertinib | Biomed Valley Discoveries.
  2. Oxford University Press. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel ...
  3. UCSF Clinical Trials. Ulixertinib in Treating Patients With Advanced Solid Tumors, Non ...
  4. Pharmaceutical Technology. Ulixertinib by BioMed Valley Discoveries for Hematological Tumor.
  5. BioSpace. xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523).

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.